Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

'Grand Slam' Pancreatic Cancer Drug Shows Promise as First-Line Treatment

MedPage TodayView source article

Part of story

Pancreatic cancer pill daraxonrasib shows 61% response rate in early trial

A new KRAS-targeted oral drug, daraxonrasib, shrank tumors in a majority of patients with advanced pancreatic and lung cancers in an early-stage trial, with some tumors disappearing entirely. Experts are calling it a potential major breakthrough in pancreatic cancer treatment.

Nov 20, 2026·4 sourcesDrug Policy, Pricing & ApprovalCancer & OncologyClinical trialsCancer treatmentTargeted cancer therapyFDA drug approvalCancer and Cancer TreatmentCancer treatment breakthroughs
Pancreatic cancer pill daraxonrasib shows 61% response rate in early trial
00

Other sources for this story

Reuters

Erasca's pill shrinks hard-to-treat pancreatic and lung tumors in early-stage trial | Reuters

Gulf News

New pancreatic cancer pill makes tumours disappear in some patients

BBC

Massive hope for pancreatic cancer pill after trial saw tumours vanish